➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
McKinsey
Harvard Business School
Mallinckrodt
Johnson and Johnson

Last Updated: October 24, 2021

DrugPatentWatch Database Preview

Endo Pharms Company Profile


Email this page to a colleague

« Back to Dashboard

Summary for Endo Pharms
International Patents:298
US Patents:24
Tradenames:16
Ingredients:14
NDAs:20

Drugs and US Patents for Endo Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-004 Jun 22, 2006 DISCN Yes No 7,276,250 ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-006 Feb 29, 2008 DISCN Yes No 8,309,112 ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-003 Dec 9, 2011 DISCN Yes No 8,192,722 ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Endo Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-001 Jun 22, 2006 5,128,143 ⤷  Free Forever Trial
Endo Pharms FROVA frovatriptan succinate TABLET;ORAL 021006-001 Nov 8, 2001 5,827,871 ⤷  Free Forever Trial
Endo Pharms MOBAN molindone hydrochloride TABLET;ORAL 017111-007 Approved Prior to Jan 1, 1982 3,491,093 ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ENDO PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 5 mg, 10 mg, 20 mg and 40 mg ➤ Subscribe 2007-11-23
➤ Subscribe Extended-release Tablets 30 mg ➤ Subscribe 2008-06-12
➤ Subscribe Injection 250 mg/mL ➤ Subscribe 2014-06-11
➤ Subscribe Gel 10 mg/actuation ➤ Subscribe 2012-08-14
➤ Subscribe Extended-release Tablets 7.5 mg and 15 mg ➤ Subscribe 2008-05-29
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 2011-03-09
➤ Subscribe Nasal Spray 500 mcg/spray ➤ Subscribe 2017-04-28

Supplementary Protection Certificates for Endo Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0694547 SPC/GB02/027 United Kingdom ⤷  Free Forever Trial PRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425
0694547 2002/028 Ireland ⤷  Free Forever Trial PRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013
0591280 01C0019 France ⤷  Free Forever Trial PRODUCT NAME: FROVATRIPTAN SUCCINATE MONOHYDRATE; NAT. REGISTRATION NO/DATE: NL 24548 20001212; FIRST REGISTRATION: FR - NL 24548 20001212
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Boehringer Ingelheim
McKinsey
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.